Extracellular matrix and the regulation of adaptive immune responses

细胞外基质和适应性免疫反应的调节

基本信息

  • 批准号:
    8091447
  • 负责人:
  • 金额:
    $ 7.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): FoxP3+ regulatory T-cells (T-reg) are thought to be crucial arbiters of immune tolerance. Unfortunately, protocols that have successfully induced FoxP3+ regulatory T-cells (T-reg) in vitro involve levels of TGFb and IL-2 that would be toxic if administered systemically in vivo. Our preliminary data, however, suggests that it is possible to deliver this same set of T-reg induction cues in a local manner by inculcating TGFb, IL-2 and anti-CD3 Ab into a hydrogel platform made of hyaluronan (HA) and heparin sulfate (HS). This approach roughly doubles the number FoxP3+ cells seen with soluble agents. My hypothesis is that antigen specific Treg can be induced from CD4+FoxP3- precursors using similar HA/HS hydrogels. I propose to investigate this hypothesis in three aims: 1) I will elucidate the mechanisms by which HA and HS in crosslinked form promote Treg induction. 2) I will optimize polyclonal Treg induction using HA/HS hydrogels. 3) I will develop HA/HS hydrogels to induce antigen specific Treg. This work is a culmination of my K08 funded research on HA and the promotion of immune tolerance. This R03 will potentially set the stage for studies on the in vivo and in situ induction of antigen specific tolerance in mouse models of diabetes that I hope to pursue in an R01 application. The significance of the planned work lies in the potential to induce antigen specific tolerance without systemic immune suppression in tissue transplantation and in the treatment of autoimmune diseases. PUBLIC HEALTH RELEVANCE: The treatment of autoimmune disease and organ transplantation frequently involves the administration of systemic immunosuppressants, often leading to infection or unacceptable toxicities. Recent efforts at inducing FoxP3+ regulatory T-cells (T-reg), the body's own mediators of immune tolerance, have faced the same limitations. Our preliminary data, however, suggests that it is potentially possible to locally deliver a set of costimulatory cues previously reported to induce T-reg by using hydrogel constructs made of hyaluronan and heparin sulfate as a platform. In this application I propose to develop hydrogels that are capable of inducing tolerance in an antigen specific manner. The significance of this planned work lies in the potential to induce tolerance to specific autoantigens or transplanted tissues without the need for systemic immunosupression.
描述(由申请方提供):FoxP 3+调节性T细胞(T-reg)被认为是免疫耐受的关键仲裁者。不幸的是,已经成功地在体外诱导FoxP 3+调节性T细胞(T-reg)的方案涉及如果在体内全身施用则将是有毒的TGF β和IL-2的水平。然而,我们的初步数据表明,有可能通过将TGF β、IL-2和抗CD 3 Ab灌输到由透明质酸(HA)和硫酸肝素(HS)制成的水凝胶平台中,以局部方式递送这组相同的T-reg诱导线索。这种方法使可溶性试剂中观察到的FoxP 3+细胞数量大致加倍。 我的假设是,抗原特异性Treg可以使用类似的HA/HS水凝胶从CD 4 + FoxP 3-前体诱导。我建议从三个方面研究这一假说:1)我将阐明交联形式的HA和HS促进Treg诱导的机制。2)我将使用HA/HS水凝胶优化多克隆Treg诱导。3)我将开发HA/HS水凝胶来诱导抗原特异性Treg。 这项工作是我的K 08资助的关于HA和促进免疫耐受的研究的高潮。该R 03将潜在地为在糖尿病小鼠模型中体内和原位诱导抗原特异性耐受的研究奠定基础,我希望在R 01应用中继续进行该研究。 计划工作的意义在于在组织移植和自身免疫性疾病的治疗中诱导抗原特异性耐受而没有全身免疫抑制的潜力。 公共卫生关系:自身免疫性疾病和器官移植的治疗经常涉及全身性免疫抑制剂的施用,经常导致感染或不可接受的毒性。最近在诱导FoxP 3+调节性T细胞(T-reg)(身体自身的免疫耐受介质)方面的努力也面临着同样的局限性。然而,我们的初步数据表明,有可能通过使用由透明质酸和硫酸肝素制成的水凝胶结构作为平台,局部递送先前报道的诱导T-reg的一组共刺激线索。在本申请中,我提出开发能够以抗原特异性方式诱导耐受性的水凝胶。这项计划工作的意义在于诱导对特异性自身抗原或移植组织耐受的潜力,而不需要全身免疫抑制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paul L Bollky其他文献

Paul L Bollky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paul L Bollky', 18)}}的其他基金

Circulating Bacteriophages for the Diagnosis of Sepsis
用于诊断脓毒症的循环噬菌体
  • 批准号:
    10673035
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
Studies on bacteriophages in respiratory diseases
噬菌体在呼吸系统疾病中的研究
  • 批准号:
    10525104
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
Circulating Bacteriophages for the Diagnosis of Sepsis
用于诊断脓毒症的循环噬菌体
  • 批准号:
    10510456
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
Studies on bacteriophages in respiratory diseases
噬菌体在呼吸系统疾病中的研究
  • 批准号:
    10669271
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
The Role of Hyaluronan and CD44 in the Pathogenesis of Type 2 Diabetes
透明质酸和 CD44 在 2 型糖尿病发病机制中的作用
  • 批准号:
    10578727
  • 财政年份:
    2020
  • 资助金额:
    $ 7.72万
  • 项目类别:
The Role of Hyaluronan and CD44 in the Pathogenesis of Type 2 Diabetes
透明质酸和 CD44 在 2 型糖尿病发病机制中的作用
  • 批准号:
    10359164
  • 财政年份:
    2020
  • 资助金额:
    $ 7.72万
  • 项目类别:
The Development of 4-methylumbelliferone Pro-drugs to Prevent Autoimmune Diabetes
预防自身免疫性糖尿病的 4-甲基伞形酮前药的开发
  • 批准号:
    9901521
  • 财政年份:
    2018
  • 资助金额:
    $ 7.72万
  • 项目类别:
Biofilms and Bacteriophages in Chronic Wound Infections
慢性伤口感染中的生物膜和噬菌体
  • 批准号:
    9375747
  • 财政年份:
    2017
  • 资助金额:
    $ 7.72万
  • 项目类别:
Extracellular matrix and the function and stability of FoxP3+ regulatory T-cells
细胞外基质与 FoxP3 调节性 T 细胞的功能和稳定性
  • 批准号:
    8345146
  • 财政年份:
    2012
  • 资助金额:
    $ 7.72万
  • 项目类别:
Extracellular matrix and the function and stability of FoxP3+ regulatory T-cells
细胞外基质与 FoxP3 调节性 T 细胞的功能和稳定性
  • 批准号:
    9135339
  • 财政年份:
    2012
  • 资助金额:
    $ 7.72万
  • 项目类别:

相似海外基金

Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens
针对 1 型糖尿病自身抗原的工程化 TCR-Treg 细胞疗法
  • 批准号:
    10764143
  • 财政年份:
    2023
  • 资助金额:
    $ 7.72万
  • 项目类别:
Study of identification for autoantigens in a mouse model of pituitary dysfunction induced by CTLA-4 or PD-1 blockade
CTLA-4或PD-1阻断诱导的垂体功能障碍小鼠模型中自身抗原的鉴定研究
  • 批准号:
    22K08648
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens
针对 1 型糖尿病自身抗原的工程化 TCR-Treg 细胞疗法
  • 批准号:
    10545634
  • 财政年份:
    2022
  • 资助金额:
    $ 7.72万
  • 项目类别:
identification of autoantigens of autoimmune pancreatitis
自身免疫性胰腺炎自身抗原的鉴定
  • 批准号:
    21H02901
  • 财政年份:
    2021
  • 资助金额:
    $ 7.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Genetic Basis of Variable Expression of Glycan Xeno-Autoantigens by Cattle
牛聚糖异种自身抗原变异表达的遗传基础
  • 批准号:
    DP200103734
  • 财政年份:
    2020
  • 资助金额:
    $ 7.72万
  • 项目类别:
    Discovery Projects
The study to identify novel pathogenesis and autoantigens in patients with membranous nephropathy
确定膜性肾病患者新发病机制和自身抗原的研究
  • 批准号:
    19K08694
  • 财政年份:
    2019
  • 资助金额:
    $ 7.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10356015
  • 财政年份:
    2019
  • 资助金额:
    $ 7.72万
  • 项目类别:
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10093988
  • 财政年份:
    2019
  • 资助金额:
    $ 7.72万
  • 项目类别:
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10560561
  • 财政年份:
    2019
  • 资助金额:
    $ 7.72万
  • 项目类别:
Identification of autoantigens presented by specific HLA class I alleles in aplastic anemia
再生障碍性贫血中特定 HLA I 类等位基因呈现的自身抗原的鉴定
  • 批准号:
    19H03686
  • 财政年份:
    2019
  • 资助金额:
    $ 7.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了